Echocardiographic and angiocardiographic features. Am J Cardiol 37: 911, 1976 Multiclinic Controlled Trial of Bethanidine and Guanethidine in Severe Hypertension VETERANS ADMINISTRATION COOPERATIVE STUDY GROUP ON ANTIHYPERTENSIVE AGENTS SUMMARY One hundred and eight patients with initial diastolic blood pressure in the range of 100-124 mm Hg while taking hydrochlorothiazide were assigned randomly and double-blind to hydrochlorothiazide plus either bethanidine or guanethidine. The average reduction of the fifth and sixth months' diastolic blood pressure was 18.4 mm Hg for guanethidine and 13.6 mm Hg for bethanidine (P < 0.01). The distribution of the individual values was such that 68.8% of guanethidine treated patients achieved a diastolic GUANETHIDINE AND BETHANIDINE are potent antipressor compounds with a similar mode of action involving blockade of the post ganglionic adrenergic nerve endings. In clinical practice guanethidine has been employed chiefly when other drugs such as diuretics, hydralazine, reserpine or methyldopa fail to achieve adequate control of the hypertension or when their side effects are unaccept-level below 90 mm Hg, compared to only 45.5% of the bethanidine treated group (P < 0.025). The degree of orthostatic fall in blood pressure was greater with bethanidine than with guanethidine (P < 0.05). The diurnal variation of blood pressure was slightly greater with bethanidine than with guanethidine. The results significantly favor guanethidine. This study failed to demonstrate that the shorter action of bethanidine confers significantly better control of blood pressure than the longer action of guanethidine.
able.", 2 It has also been used as the primary agent to control malignant or severe diastolic hypertension in combination with diuretics and other antihypertensive drugs.2 8 Bethanidine is not commercially available in the United States, but is widely used in Britain." It is said to have the following advantages over guanethidine:4 "1-1) Following oral administration the onset of antihypertensive effect occurs within one or two hours, reaches a maximum at four to five hours and disappears in 12 hours. By contrast, the duration of action of guanethidine is greater than 96 hours.9 Because of its short action in comparison with guanethidine, bethanidine might avoid the morning orthostatic hypotension as well as the afternoon rise of blood pressure characteristic of guanethidine. By varying the doses of bethanidine at different times of the day, it might be possible to minimize the diurnal fluctuation of blood pressure that is seen with guanethidine.
2) Side effects are an inseparable byproduct of the pharmacological action of both drugs, but they are said to be more severe with guanethidine. Increased frequency of bowel movements, which may be a troublesome side effect of guanethidine, is said to be absent with bethanidine.4 Orthostatic faintness, sexual dysfunction and mild depression also occur in varying degrees with both guanethidine and bethanidine. However, because of the shorter duration of action of bethanidine, the ability to control or minimize the side effects by dosage adjustments might be greater than with guanethidine.
The purpose of the present controlled trial was to ascertain whether bethanidine plus thiazide is more effective than guanethidine plus thiazide in the control of severe hypertension.
Objectives of Study
The study was designed to determine: 1) The antihypertensive effectiveness of bethanidine as compared to guanethidine (both being combined with hydrochlorothiazide), using the following criteria: a) the percentage of patients in each group who at the fifth and sixth month postrandomization visits exhibited an average diastolic blood pressure below 90 mm Hg; b) the mean changes of diastolic blood pressures between the last two prerandomization visits (hydrochlorothiazide alone), and the fifth and six month postrandomization visits (hydrochlorothiazide plus either bethanidine or guanethidine).
2) The intrapatient diurnal variation of blood pressures with both drugs as determined by eight blood pressure readings during a 24 hour period of hospitalization. The readings were obtained during the fifth and sixth months postrandomization.
3) The acceptability of the drug combinations over a six month experience to be based on the incidence of toxic reactions and side effects. This was a double blind trial. Accepted patients were assigned randomly to either bethanidine or guanethidine under the code name "Bethadine." "Bethadine" was supplied in three strengths in a ratio of 1 mg guanethidine to 1.67 mg bethanidine as follows: All patients were continued on their usual doses of hydrochlorothiazide and one tablet every eight hours of the first strength of "Bethadine" was added.
Plan of Investigation
Patients were seen in the clinic at two week intervals and both clinic and home records of blood pressure were used in adjusting doses. "'Bethadine" doses were increased slowly by predetermined increments until an antihypertensive effect was obtained. For more precise dosage adjustments, the patients were asked whenever needed to spend from 8:00 a.m. to 4:00 p.m. in the clinic where their blood pressure was recorded every two hours. An attempt was made in each case, utilizing home and all day clinic blood pressure readings, to alter each of the three doses of "Bethadine" in order to obtain the best possible 24 hour control of the hypertension. For example, at the third and fifth month clinics, doses were changed in approximately 25% of the patients. Half of these changes took advantage of bethanidine's shorter action: either the evening dose was decreased or the morning or noon dose was increased. The minimum dose was one tablet daily of "Bethadine" strength 1, and the maximum was nine tablets of strength 3.
After the initial dosage adjustment phase, patients were seen at monthly intervals. At the fifth and sixth month visits, the patients were hospitalized and their blood pressures measured eight times during the diurnal cycle from 6:00 a.m. to 10:00 p.m. At the sixth month, all initial laboratory tests were repeated.
The following hypertensive complications were indications for removal from the study: grade 3 or 4 hypertensive retinopathy, acute hypertensive encephalopathy, hemorrhagic stroke, dissecting aneurysm of the aorta, congestive heart failure and uremia.
Terminating atherosclerotic complications included cerebral thrombosis, transient ischemic attacks, myocardial infarction and unstable angina.
Other reasons for removal of the patients were intolerance to hydrochlorothiazide, inability to tolerate the minimal dose of "Bethadine," discontinuation of protocol drugs for two months, and elevation of diastolic blood pressure One hundred and eight patients in seven hospitals were randomized: 56 to guanethidine and 52 to bethanidine. Because of losses occuring during the first six months after randomization, 48 patients receiving guanethidine and 44 receiving bethanidine completed six months of treatment.
The present results cover this period of therapy. Characteristics of the patients at the time of randomization are shown in table 1. Except for a slight difference in body weight, the data were similar in the two groups.
At the end of six months of treatment, the distributions of dose levels reached by titration for both agents were similar in relation to the 1 to 1.67 ratio guanethidine to bethanidine which was chosen to equalize tablet potencies (table 2) . Patients taking guanethidine were titrated to dose levels from a minimum of 7.5 mg/day to 150 mg/day, with the median at 30 mg/day. Patients receiving bethanidine were titrated to dose levels from a minimum of 12.6 mg/day to 350 mg/day with the median at 50 mg/day.
Blood Pressure Changes
The therapeutic end point was a sitting phase 5 diastolic blood pressure measured with the Arteriosonde of less than 90 mm Hg using the average of the readings taken at the fifth and sixth months postrandomization. This end point was achieved in 68.8% of patients treated with guanethidine and in 45.5% of the bethanidine treated group (P < 0.025) ( fig. 1 ).
The number and percent frequencies of the changes in sitting pressures before and after treatment are shown in figure  2 . Eighty-five percent of the patients on guanethidine compared to 70.5% of the patients on bethanidine obtained a diastolic pressure reduction exceeding 10 mm Hg. The mean reduction with guanethidine was 18.4 mm Hg, which was significantly greater than the 13.6 mm Hg obtained with bethanidine (P < 0.01). .\initial The average systolic blood pressures in the supine position were essentially equal in both groups but in the orthostatic position, the systolic diurnal range of change averaged 14.0 mm Hg for guanethidine and 22.7 mm Hg for bethanidine, a difference of 8.7 mm Hg (P < 0.05). The diurnal range of change in diastolic blood pressure from supine to standing averaged 1.9 mm Hg for the guanethidine group and 6.3 mm Hg for the bethanidine group; the difference of 4.4 mm Hg is also significant (P < 0.05). In fact, the averages of all systolic and diastolic supine-erect blood pressure changes at all times of the day were greater with bethanidine than with guanethidine. Table 4 shows the averages of the lowest and highest daily pressures of the 36 patients in the supine, sitting and erect positions. The pooled within-patient, within-day standard deviations of eight observations for each position from 6:00 a.m. to 10:00 p.m. are also shown. All differences between average highest and lowest systolic and diastolic pressures in all positions were greater for bethanidine than for guanethidine. The standard deviations were also uniformly greater for bethanidine than for guanethidine in all positions for both systolic and diastolic blood pressures.
Postural and Diurnal Changes in Blood Pressure

Comparison of Pressure Readings with the Arteriosonde and the Standard Auscultatory Method
Standard auscultatory blood pressures also were taken at the same time as the Arteriosonde readings at prerandomization and five and six months postrandomization. In the prerandomization determinations it was observed that the systolic readings were almost identical for both methods with an average difference of only 1.04 mm Hg (table 1) No differences between drugs were noted with respect to frequency of bowel movements, vertigo and syncope.
No significant differences between the groups were noted in serum potassium or uric acid. There was a trend to a slight increase in serum creatinine averaging less than 0.3 mg % with guanethidine, but neither the change nor the differences between the regimens were statistically significant.
It was noted in table 1 that the initial average heart rate for patients randomized to guanethidine was 79.8/min and for those on bethanidine 81/min. After six months of treatment the average heart rate decreased 6/min with guanethidine and increased 1.2/min with bethanidine. This difference is significant (P< 0.01). 
Discussion
Using the end point of sitting fifth phase diastolic levels below 90 mm Hg after'six months of treatment, it would appear that guanethidine was more effective than bethanidine. Over 23% more patients achieved this end point with guanethidine than with bethanidine. Similarly, using the end point of fifth phase diastolic blood pressure reduction, guanethidine was more effective. With guanethidine the average reduction was 4.8 mm Hg greater than with bethanidine. Both differences were significant statistically.
Guanethidine also showed a greater antihypertensive effect than bethanidine according to other indicators. For example, 85.3% of guanethidine treated patients achieved a reduction of diastolic pressure exceeding 10 mm Hg compared to 70.5% of those taking bethanidine. Likewise, sitting systolic pressure was reduced more effectively and in a greater proportion of patients with guanethidine than with bethanidine. The spread between the two regimens was even greater with the established, standard auscultatory technique with 81.2% of guanethidine treated patients and only 50% of bethanidine treated subjects achieving a reduction in diastolic pressure exceeding 10 mm Hg. These findings are in contrast to previous reports. Gibb et al., in a smaller controlled trial, found no essential difference between guanethidine and bethanidine.5 These drugs have been considered to be interchangeable in terms of antihypertensive effectiveness.'0
Other objectives of the study were to determine whether one drug induced less orthostatic change than the other throughout the day and at different times of the day. The means of the values obtained in the throughout-the-day measurements indicate that the orthostatic fall obtained from supine to standing with bethanidine averaged 8.7/4.4 mm Hg more than that obtained with guanethidine. The greater differential between supine and erect blood pressures with bethanidine was noted throughout the day including the early morning blood pressures. These results were disappointing because it was hoped that with the greater ability to adjust dosages at eight hour intervals, the spread between supine and orthostatic levels would be less with bethanidine than with guanethidine. Prichard et al. in a cross-over study also found that bethanidine produced slightly greater orthostatic hypotension than did guanethidine. 6 Contrary to what was anticipated,7 8 the diurnal variation in blood pressure was not significantly different between the drugs. Indeed, the small differences observed favored guanethidine. Bethanidine exhibited greater differences than guanethidine between the means of the highest and lowest systolic and diastolic blood pressures measured throughout the day from 6:00 a.m. to 10:00 p.m. Also, the pooled withinpatient, within-day standard deviations of eight observations throughout the day were slightly greater with bethanidine than with guanethidine. These findings were noted in all positions, but were particularly notable in the orthostatic position.
Considering the severity of the hypertension, the number of morbid events was not great. Also, three of the four were atherosclerotic complications involving the coronary and cerebral vessels. The distribution of morbid events was about the same with both treatments. The preponderance of atherosclerotic complications in this short term study is similar to that among the treated patients of the Veterans Administration Study on morbidity," 12 where treatment appeared to be effective primarily in preventing the so-called "hypertensive" complications of hemorrhagic stroke, congestive heart failure, renal failure and malignant phase of hypertension.
No significant differences were noted in the side effects in our patients. Fewer patients taking bethanidine complained of dyspnea and depression than was the case with guanethidine. Surprisingly, however, there was no difference in the two groups in regard to increased frequency of bowel movements, the absence of which is claimed as one of the main advantages of bethanidine. The incidence of sexual dysfunction, lethargy and syncope also were similar in the two therapeutic groups.
The lack of significant difference in the incidence of complaints of side effects does not necessarily indicate that such differences may not actually exist. In the present study, a relatively high incidence of complaints of side effects was observed in both treatment groups. In a previous V.A. drug trial,'2 it was noted that placebo treated patients can exhibit as high an incidence of suspected side effects as patients taking active drugs. It is our impression that the clinic interview technique yields a large number of false positive responses which may result in dilution of actual differences to the extent that they become undetectable.
Guanethidine produced a small but significant lowering of pulse rate as compared to bethanidine. Prichard et al. noted the same effect.6 This may be attributed to a more complete sympathetic inhibition and consequent increase in parasympathetic effect by guanethidine as compared to bethanidine. Although both drugs inhibit the release of noradrenaline at the sympathetic nerve endings, bethanidine does not deplete noradrenaline in nerve tissue until several months have elapsed, and even then to a lesser degree than guanethidine. 8 The results of the present study fail to support the claim that bethanidine provides greater therapeutic benefit than guanethidine. In fact, the results significantly favor guanethidine over bethanidine. The shorter duration of action of bethanidine apparently does not confer an advantage in more effective control of blood pressure than the longer action of guanethidine. It must be emphasized, however, that the study was designed and the results analyzed to determine the relative effectiveness of the drugs in two groups of patients. It is entirely possible that certain individual patients may obtain more therapeutic benefit from bethanidine than from guanethidine and vice versa.
ISOPROTERENOL, a potent beta-adrenergic stimulator, has been widely used for the treatment of cardiac failure, cardiogenic shock, or low output syndrome following open heart surgery. [1] [2] [3] Although infusion of isoproterenol improves myocardial performance, occurrence of adverse side effects such as tachycardia, ventricular arrhythmia, and reduced perfusion pressure, often necessitates the discontinuation of this drug. Furthermore, isoproterenol has been shown experimentally to intensify myocardial ischemia and to extend infarct size after coronary narrowing or occlusion resulting in acute myocardial failure. 4 An agent with inotropic effect as potent as isoproterenol but without significant effects on vasomotor tone, heart rate, or rhythm would be desirable for the treatment of myocar-from 33.4 ± 2.3 to 37.1 ± 2.5 mm Hg with 8 Ag/kg/min, while other pressures were unchanged. Mean left atrial pressure fell significantly from 15.9 ± 0.6 to 14.8 ± 0.7 mm Hg. Stroke volume index, stroke work index, and left ventricular work also increased. Premature ventricular beats were observed in only one patient during dobutamine infusion, but no other side effect was observed.
We conclude that dobutamine is a potent inotropic agent which increases cardiac output without causing significant tachycardia or arrhythmias, and is useful for the treatment of patients following open heart surgery. dial pump failure. Recently, Tuttle and Millis synthesized a new beta-adrenergic stimulator.6 This new beta-adrenergic stimulator, dobutamine, which is synthesized by modifying the side-chain of dopamine, is reported to have a strong inotropic action with a weak chronotropic action and little effect on peripheral vessels. [7] [8] [9] [10] [11] [12] [13] [14] In this study, we examined the acute hemodynamic effects of dobutamine on patients following open heart surgery and compared the hemodynamic responses with isoproterenol infusion.
Method and Materials
The study group (table I) 
